Corticosteroids and Skeletal muscle function in Cystic Fibrosis.

Sinead C. Barry BSc PhD

Charles G. Gallagher FRCPI FCCP,

Department of Respiratory Medicine and the National Referral Centre for Adult Cystic Fibrosis,

St. Vincent’s University Hospital,

Dublin 4,

Ireland.

Running Head: Steroid Myopathy in Cystic Fibrosis

Correspondance to

Dr. Charles G. Gallagher,

Department of Respiratory Medicine,

St. Vincent’s University Hospital,

Dublin 4,

Ireland.

Phone No. 00353-1-2094938

Fax No. 00353-1-2094989

Email v.hearn@st-vincents.ie

Key words: Steroids, Peripheral muscle strength, Respiratory muscle strength
Abstract:

Background: Patients with Cystic Fibrosis (CF) have reduced peripheral muscle strength. We tested the hypothesis that steroid treatment contributes to muscle weakness in adults with CF. Methods: 23 stable CF patients were studied. Measurements included knee extensor (KE), knee flexor (KF), elbow flexor (EF), handgrip (HG), expiratory (Pemax) and inspiratory (Pimax) muscle strengths. Spirometry, body mass index (BMI) and days spent in hospital over the preceding 12 months (DH) were also measured. Average daily dose of prednisolone over the preceding 12 months (ADD) was 5.1mg per day. Results: Pearson's correlation analysis revealed that ADD correlated significantly with skeletal muscle strengths (KF%, r=0.63, p<0.01) with the exception of HG%. These findings are independent of age, BMI, pulmonary function and DH. Multiple regression analysis revealed that, ADD was the most significant predictor of all measures of skeletal muscle function except HG%. It was independently responsible for 54% of the variance in Pimax%, for 46% of the variance in Pemax%, for 45% of the variance in KE%, for 39% of the variance in KF% and for 41% of the variance in EF%. Concomitant medications (e.g. theophylline) were shown to have no causative effect. Conclusion: Corticosteroids contribute to the skeletal muscle weakness seen in CF patients. The correlation of proximal muscle strength, but not handgrip strength, with steroid dosage further supports a cause-effect relationship.
Introduction

Many patients with Cystic Fibrosis (CF) have weak peripheral (9, 24) and, in some cases respiratory muscles (23, 34). There is evidence that muscle weakness in CF may have major clinical implications (9, 16). Generalised muscle weakness may occur as a result of malnutrition (3, 14), disturbance in serum electrolytes (4), hypoxia, (7, 8) and disuse (5, 15). Respiratory muscle weakness is often related to hyperinflation and poor nutrition (23, 34), however preservation of respiratory strength has also been demonstrated in some CF patients despite the presence of low body weight and significant hyperinflation. Recent work by Decramer et al (12) in chronic obstructive pulmonary disease (COPD) has demonstrated a significant relationship between steroid usage and both peripheral and respiratory muscle strength. The affect of steroid use on muscle strength in CF has not been examined to date. Despite the well known negative side affects associated with chronic corticosteroid use, steroids still form an important part of the management of many patients with CF (6, 22, 33, 35).

We hypothesised that the muscle weakness seen in CF may be related in part to steroid use. We examined the relationship between skeletal muscle strength and steroid dosage (average daily dose in the previous year) in adults with CF who were clinically stable. We wanted to minimize the possibility that factors other than steroid usage might affect any relation between steroid dosage and muscle weakness. Therefore we also examined the relation between skeletal muscle strength (dependent variable) and spirometry, nutritional status, and number of days spent in hospital over the previous year. Steroid myopathy preferentially affects proximal muscles and spares distal muscle groups. Therefore we examined the relation between steroid dosage and strength of distal (eg. handgrip) muscles as well as that between steroid
dosage and strength of proximal muscles (e.g. knee flexor and extensor). We reasoned that if steroids contribute to muscle weakness in CF, proximal strength should correlate with steroid dosage but peripheral strength should not. Because acute infection or acute respiratory exacerbation may influence muscle function, patients were studied at least one month after any acute exacerbation.
Materials And Methods

Twenty-three patients (13 male, 10 female) were recruited from the outpatients department at the National Referral Centre for Adult Cystic Fibrosis at St. Vincent’s University Hospital, Dublin. Diagnosis of CF for each subject was based on clinical features, abnormal sweat test (sweat chloride > 60 mmol/l) and genotyping. All subjects were clinically stable for 1 month prior to taking part in the study.

To assess the effects of corticosteroids on skeletal muscle function we measured inspiratory (Pimax), expiratory (Pemax), knee extensor (KE), knee flexor (KF), elbow flexor (EF) and hand grip (HG) strengths. Pulmonary function tests were performed and total steroid dose over the previous 12 months was calculated in mg per day. All tests were performed during a single visit to the research laboratory. Due to both ethical and logistical difficulties, it was not possible to include a control group.

The local Ethics Committee approved the study. All patients gave informed consent to the procedures.

Corticosteroid Treatment:

The average daily dose (ADD) of corticosteroids taken during the previous 12 months was calculated. No subject in the study had taken fluorinated steroids at any time in their past. Corticosteroids included oral prednisolone and intravenous hydrocortisone. Calculation of the ADD involved examination of patient files, patient interviews, and examination of each patient’s local pharmacy notes over the preceding 12 months. The Irish Health Care system provides free medication to all patients with CF, which is paid retrospectively by the government to each pharmacy. As a result accurate records are available from the local pharmacy on all medications received by each patient. All doses were converted into prednisolone equivalent and expressed in mg.
per day. We also examined the effects of concomitant therapies (theophylline, antibiotics etc) on skeletal muscle function.

**Concurrent Medication:**

All patients involved in the study continued on their maintenance medication at the time of testing. The following is an account of all medications used by the study population prior to and during the study: 20 subjects used colomycin nebulised, 1 subject used nebulised tobramycin, 2 subjects used nebulised gentamicin, 18 used pancreatin with meals, 8 used flucloxacillin orally, 4 used cefaclor orally, 1 subject used cefuroxime orally, 1 subject took co-amoxiclav orally, 7 used omeprazole, 13 subjects used oral theophylline, 7 used dornase alpha nebulised, 4 subjects took ursodeoxycholic acid, all subjects used vitamin supplements, 15 subjects used salbutamol nebulised, 1 subject used budesonide nebulised, 21 subjects used a salbutamol inhaler, 4 subjects used ipratropium bromide and salbutamol in a combination inhaler, 11 subjects used a beclomethasone dipropionate inhaler, 1 subject used an ipratropium bromide inhaler, and 6 subjects used a fluticasone propionate inhaler.

**Pulmonary Function Testing:**

Forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) were measured using a spirometer (Vitalograph Compact 11, Fannin Ireland) using the recommendations of the American Thoracic Society (1) and predicted normal values (31) were used to calculate the percentage predicted values.

**Respiratory Muscle Strength:**

Mouth pressures during Pimax and Pemax at functional residual capacity (FRC) were measured as indices of inspiratory and expiratory muscle strength, respectively (25, 36). Pressure was measured with a transducer (P.K. Morgan Pmax), which was
calibrated with a manometer before each test. Identical methods to those used by McParland et al (26) were employed.

**Peripheral Muscle Strength:**

Static contractions were measured using the Compufet system (Biometrics, Kabelstraat, NL), which was attached to the rigid arm of the quadriceps bench. Each subject was instructed to push as hard as possible against the rigid arm of the quadriceps bench and to sustain the contraction for 8 seconds as required by the Compufet software. Visual feedback was given representing contraction time during each voluntary effort. The maximum voluntary contractions were recorded as the best of three contractions for each leg and compared with predicted values (32). Two practice efforts were performed and this was followed by sufficient tests until three were achieved within 10% of each other. Bilateral limbs were assessed and the strength of the stronger limb was used for analysis.

To assess isometric KE, KF and EF identical positions to those previously described were employed (32). An adjustable strap was used to secure the pelvis for both KE and KF and to secure the trunk for EF testing. Hand Grip strength was assessed using the same equipment and methods as previously described (26).

**Data Analysis:**

Percentage predicted values for isometric peripheral muscle strengths were calculated (32). Predictive equations for analysis of respiratory muscle strengths are those used by Hamilton et al (18).

**Statistical Analysis:**

Data are reported as mean ± SD. Correlation among variables was assessed using Pearson's correlation coefficient. Stepwise multiple regression analysis was performed
for muscle strengths; variables used in the model included age, gender, BMI, FEV1% and days spent in hospital over the preceding 12 months. Only variables significantly contributing to the model were retained in the final analysis and the limits of significance were set at p< 0.05.
Results

Patient Characteristics

Patient characteristics are summarised in Table 1. The population was quite diverse with regard to disease state. Nutritional status ranged from significantly malnourished (BMI = 16.4), to normal (BMI = 25.5), while airflow obstruction ranged from normal (FEV1= 108% predicted), to severely obstructed (FEV1= 25% predicted). Inspiratory muscle strength ranged from 40% predicted to 175% predicted. Expiratory muscle strength also demonstrated a similar spread with values ranging from 30-166% predicted (Table 2). Limb muscle strength also demonstrated a wide variation from significantly weak to normal levels (EF% = 24%-105%) but mean strength was reduced for all limb muscles tested.

Average daily dose of prednisolone over the preceding 12 months (ADD) was 5.1mg per day. No subject was treated with corticosteroids for Allergic Bronchopulmonary Aspergillosis.

Relationship between limb muscle and respiratory muscle strengths

Respiratory muscle strength and limb muscle strength correlated significantly with each other (p<0.05); Pimax% correlated with KE% (r=0.76), KF% (r=0.64), EK% (r=0.87), HG% (r=0.47) and Pemax% (r=0.84). Pemax% was also significantly correlated with limb muscle strength, KE% (r=0.73), KF% (r=0.62), EK% (r=0.83) and HG% (r=0.51).
Relationship between Muscle Strength and Steroid Treatment

Using Pearson's correlation analysis (Table 3) (Figure 1), we assessed the relationship between limb muscle and respiratory muscle strength and steroid dose, and found a significant relationship between ADD and KE%, KF%, EF%, Pimax% and Pemax%.

Relationship between Muscle Strength and BMI, FEV1%, age and hospital days (DH).

The relationships between muscle forces and BMI, FEV1%, age and DH were tested using Pearson's correlation analysis. (Table 3) (Figure 2) BMI was chosen as a marker of nutritional status in CF. No significant correlations were identified between age and any of the variables of muscle function nor between DH and any of the variables of muscle function. Significant positive correlations were identified between BMI and both Pimax% and Pemax%. Significant positive correlations were also found between FEV1% and KE%, Pimax% and Pemax%. Significant negative correlations were identified between ADD and all measures of muscle strength except HG%. The correlations found between ADD and KE% and ADD and respiratory muscle strength (Pimax% and Pemax%) were more significant than those seen between FEV1% and KE% and FEV1% and respiratory muscle strength.
Determinants of muscle forces using Stepwise Multiple Regression Analysis

Average daily dose predicted 45% of the variance in KE% with gender being responsible for 24%. (Table 4) Thirty-nine percent of the variance in KF% was due to ADD. Forty-one percent of the variance in EF% was related to ADD with gender being responsible for a further 36%. HG% had no significant predictors. ADD predicted 54% of the variance in Pimax%, with 9% being due to BMI and 13% being due to gender. ADD also explained 46% of the variance in Pemax% with 22% being related to gender. For all muscle groups tested except HG%, ADD of corticosteroids explained the largest proportion of muscle weakness seen. (Table 4) None of the concurrent medications contributed significantly to the regression model. Figure 3 illustrates the lack of correlation between theophylline dose expressed in mg/day and KE%.
Discussion

The major new findings of this work are: that 1) corticosteroid treatment independently correlates with limb and respiratory muscle strength in patients with CF 2) the effects of corticosteroid treatment on skeletal muscle function are independent of airflow obstruction, nutrition and days spent in hospital and 3) this correlation is seen for proximal muscles but not for the distal handgrip muscles. These results are in support of the hypothesis that treatments with corticosteroids have a negative effect on skeletal muscle strength in CF patients.

Possible limitations of this study are: 1) that we used an indirect measurement of nutritional status, and no direct measure of lean body mass was performed. However BMI has been shown to be a valuable measure of nutritional status in CF and to relate to exercise capacity (28), bone mineral density (17) and prognosis (20), 2) our measures of limb muscle strength and respiratory muscle strength are effort dependent; however each subject was tested repeatedly by the same investigator making it difficult to perform repeated submaximal efforts, 3) we did not measure total body muscle mass and as a result it is difficult to say conclusively whether we are seeing true myopathy, where strength would be reduced at a disproportionate rate to muscle mass and 4) DH provides a useful marker of periods of extreme disuse however activity of daily living may contribute to disuse atrophy and has not been accounted for here.
A number of authors have looked at the presence of limb muscle weakness in CF patients. Lands et al (24) demonstrated that leg strength was reduced in CF patients compared to controls and strength was strongly related to body mass \((r = 0.816, p<0.01)\). Mier et al (27) found that quadriceps strength was on average 68% predicted in their CF group. More recently de Meer (9) demonstrated that limb muscle force was reduced in CF children even in the absence of reduced pulmonary or nutritional status, while Elkin et al (16) have demonstrated that both limb muscle strength and mass were reduced in their CF group compared to controls. The causes of muscle weakness in CF remain unclear; some authors suggest impairment in the quality of the muscle (9-11, 29), while others suggest that the differences in strength seen between CF patients and controls are related to body mass (16, 19, 24). No conclusive data are available at this time.

Studies of respiratory muscle function in CF are difficult to compare because of differences in the age of subjects studied, the methods used and the indices of muscle function. The tendency throughout the literature has been for inspiratory strength to be preserved in CF (20, 23, 24, 27, 30) and this is in agreement with our findings.

Significant negative correlations were found between Pimax\%, Pemax\% and ADD. (Table 3) Our results demonstrate a wide range of values for Pimax\% (39.9 %– 175\%) with an equally wide range seen for Pemax\% (30.6%-166.1\%). We have shown that some patients have preserved respiratory muscle strength, while others have markedly reduced strength and still others have supernormal levels of respiratory muscle strength. The mechanisms responsible for these variations in strength are not clear. Factors such as reduced nutritional status, hypoxia, acidosis, electrolyte disturbances and disuse may contribute to reduced strength, while chronic cough and increased
work of breathing have been implicated in both preserved and increased respiratory muscle strength. It is likely that a number of factors simultaneously cause respiratory muscle variation. We have demonstrated a relationship between the widely varying respiratory strength seen in adults with CF and ADD, which have not been described previously.

There are many possible factors, which can affect skeletal muscle function in CF. Weight loss, protein calorie insufficiency, abnormal ion transport, inflammation, sepsis, electrolyte disturbances, hypoxia and corticosteroid usage all have myopathic potential. The purpose of this study was to assess the independent effects of corticosteroid therapy on limb muscle strength and respiratory muscle strength in a group of stable CF patients. It is known that myopathy may occur with virtually all steroids in common use (2, 13, 37). There are no previous data, to our knowledge, on the effects of treatment with corticosteroids on muscle strength in CF patients.

Like others, we have demonstrated the presence of limb muscle weakness in adults with CF (9, 16, 24, 27) and the preservation, on average, of respiratory muscle strength (21, 24, 30). We have shown that ADD of corticosteroids is significantly correlated with all measures of skeletal muscle function except HG%. We were unable to identify significant predictors of HG strength. HG was on average reduced at 67.9% predicted. Possible mechanisms of reduced HG strength are similar to those already described for generalized skeletal myopathy, with the exception of corticosteroid usage. These results are in agreement with our biological knowledge of steroid myopathy and its preference for proximal muscle atrophy, hence the lack of correlation with HG%.
Stepwise multiple regression analysis revealed that ADD was responsible for the largest proportion of the muscle weakness seen in our CF patients, to a greater extent than nutritional status, pulmonary function and DH. Single Regression analysis revealed a lack of correlation between peripheral muscle forces and FEV1%, BMI, age and DH. The only significant correlation found was between KE% and FEV1%, however this correlation was less than that seen for KE% and ADD. These findings suggest that treatment with corticosteroids contributes to muscle weakness in CF patients.

Nutritional status, disuse and severity of disease all potentially affect muscle strengths in CF. To control for these potential cofactors, we assessed the effects of FEV1%, BMI, age, gender and days spent in hospital over the previous 12 months on strength of peripheral and respiratory muscles using both single and multiple regression analysis. Single regression analysis revealed a significant relationship between KE% and FEV1%, which was less significant than between KE% and ADD. Stepwise multiple regression analysis revealed that ADD was the most significant predictor of KE%, KF%, EF%, Pimax% and Pemax% with no significant effect on HG%. These results are in agreement with our hypothesis i.e. that corticosteroids contribute to skeletal muscle weakness in CF.

In conclusion, this study demonstrates a significant association between corticosteroid dosage, and skeletal muscle weakness in adults with CF. This correlation occurs at doses used in clinical practice. The correlation with steroid dosage is much greater than that attributable to age, sex, lung function or overall nutritional status. These results have significant clinical implications.
Acknowledgements:

We would like to thank the Cystic Fibrosis Research Trust, the Cystic Fibrosis Association of Ireland, the Health Research Board of Ireland and the National Rehabilitation Board of Ireland for their support. We would also like to thank the Cystic Fibrosis patients at St. Vincent’s University Hospital for their continued support.
References


15. Dudois D. Disuse atrophy of skeletal muscle is associated with an increase in number of glucocorticoid receptors. *Endocrinology* 107:1694,1980.


Figure Legend

Figure 1
Correlation of Percentage predicted Knee Extensor Strength with Average Daily Dose of Corticosteroid over the previous 12 months.

Figure 2
Correlation of Percentage predicted Knee Extensor Strength with days spent in hospital over the previous 12 months.

Figure 3
Correlation of Percentage predicted Knee Extensor Strength with Theophylline dose in mg/day over the previous 12 months.
Table 1

Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Mean(SD)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>13/10</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>23.3(5.1)</td>
<td>18-39</td>
</tr>
<tr>
<td>BMI</td>
<td>20.6(2.5)</td>
<td>16.4-25.5</td>
</tr>
<tr>
<td>FEV1%</td>
<td>48.7(24.0)</td>
<td>25-108</td>
</tr>
<tr>
<td>FVC%</td>
<td>72.3(20.6)</td>
<td>33-112</td>
</tr>
<tr>
<td>DH</td>
<td>31.0(30.9)</td>
<td>0-100</td>
</tr>
</tbody>
</table>

Data are shown as mean ± SD.

Abbreviations: FEV1% = Forced expiratory volume in 1 second expressed in percentage predicted terms; FVC% = Forced Vital Capacity expressed in percentage predicted; DH= days spent in hospital over the previous year; BMI = Body Mass Index.
Table 2

Peripheral muscle strengths expressed in percentage predicted terms.

<table>
<thead>
<tr>
<th></th>
<th>Mean(SD)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>KE%</td>
<td>45.7(17.6)</td>
<td>15.8-91.3</td>
</tr>
<tr>
<td>KF%</td>
<td>62.0(16.9)</td>
<td>31.6-95.5</td>
</tr>
<tr>
<td>EF%</td>
<td>62.6(18.1)</td>
<td>24.3-105.0</td>
</tr>
<tr>
<td>HG%</td>
<td>67.9(12.2)</td>
<td>48.8-96.7</td>
</tr>
<tr>
<td>Pimax%</td>
<td>94.1(34.2)</td>
<td>39.8-175</td>
</tr>
<tr>
<td>Pemax%</td>
<td>102.4(35.8)</td>
<td>30.6-166.1</td>
</tr>
</tbody>
</table>

Data are shown as mean ± SD.

Abbreviations: KE% = percentage predicted knee extensor strength; KF% = percentage predicted knee flexor strength; EF% = percentage predicted elbow flexor strength; HG% = percentage predicted hand grip strength; Pimax% = percentage predicted inspiratory muscle strength; Pemax% = percentage predicted expiratory muscle strength.
Table 3

Correlation analysis between muscle forces and BMI, FEV1%, age and DH

<table>
<thead>
<tr>
<th></th>
<th>KE%</th>
<th>KF%</th>
<th>EF%</th>
<th>HG%</th>
<th>Pimax%</th>
<th>Pemax%</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI</td>
<td>0.29</td>
<td>0.40</td>
<td>0.27</td>
<td>0.30</td>
<td>0.55†</td>
<td>0.54†</td>
</tr>
<tr>
<td>FEV1%</td>
<td>0.56†</td>
<td>0.39</td>
<td>0.40</td>
<td>0.23</td>
<td>0.64†</td>
<td>0.67†</td>
</tr>
<tr>
<td>ADD</td>
<td>-0.67†</td>
<td>-0.63†</td>
<td>-0.64†</td>
<td>-0.26</td>
<td>-0.73†</td>
<td>-0.67†</td>
</tr>
</tbody>
</table>

Pearson's r * p<0.05, † p<0.01

Abbreviations: ADD = Average Daily Dose of corticosteroids over the previous 12 months; KE% = percentage predicted knee extensor strength; KF% = percentage predicted knee flexor strength; EF% = percentage predicted elbow flexor strength; HG% = percentage predicted hand grip strength; FEV1% = Forced expiratory volume in 1 second expressed in percentage predicted terms; DH= days spent in hospital over the previous year; BMI = Body Mass Index.
Table 4

Stepwise Multiple Regression Analysis

$R^2$ = total variance explained by the significant components of the model

<table>
<thead>
<tr>
<th></th>
<th>KE%</th>
<th>KF%</th>
<th>EF%</th>
<th>HG%</th>
<th>Pimax%</th>
<th>Pemax%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>FEV1%</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Sex</td>
<td>0.24</td>
<td>NS</td>
<td>0.36</td>
<td>NS</td>
<td>0.13</td>
<td>0.22</td>
</tr>
<tr>
<td>DH</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>BMI</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>0.09</td>
<td>NS</td>
</tr>
<tr>
<td>ADD</td>
<td>0.45</td>
<td>0.39</td>
<td>0.41</td>
<td>NS</td>
<td>0.54</td>
<td>0.46</td>
</tr>
<tr>
<td>$R^2$</td>
<td>0.69</td>
<td>0.39</td>
<td>0.77</td>
<td>NS</td>
<td>0.76</td>
<td>0.68</td>
</tr>
</tbody>
</table>

Abbreviations: FEV1% = Forced expiratory volume in 1 second expressed in percentage predicted terms; DH = days spent in hospital over the previous year; BMI = Body Mass Index; ADD = Average Daily Dose of Corticosteroids used over the previous 12 months; KE% = knee extensor strength; KF% = percentage predicted knee flexor strength; EF% = percentage predicted elbow flexor strength; HG% = percentage predicted hand grip strength; Pimax% = inspiratory muscle strength; Pemax% = expiratory muscle strength.
A scatter plot showing the relationship between average daily dose (mg/day) and kinase extension predicted. The line of best fit has an $R^2$ value of 0.45.